ADAGENE INC. - ADS EACH REPRESENTING 1.25 ORDINAR

Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126)

16 ديسمبر 2025 07:00:00 بحسب Nasdaq GlobeNewswire

Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology

13 نوفمبر 2025 07:00:00 بحسب Nasdaq GlobeNewswire

Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer

31 أكتوبر 2025 07:00:00 بحسب Nasdaq GlobeNewswire

Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate

16 سبتمبر 2025 08:00:00 بحسب Nasdaq GlobeNewswire

Adagene’s ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, China

05 سبتمبر 2025 09:55:13 بحسب Nasdaq GlobeNewswire

Adagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive Advisor

03 سبتمبر 2025 09:05:21 بحسب Nasdaq GlobeNewswire

Adagene to Participate in Two Investor Conferences in September

26 أغسطس 2025 08:05:27 بحسب Nasdaq GlobeNewswire

Adagene Reports Six Months 2025 Financial Results and Provides Corporate Updates

12 أغسطس 2025 16:05:01 بحسب Nasdaq GlobeNewswire

Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA

15 يوليو 2025 07:00:00 بحسب Nasdaq GlobeNewswire

Adagene and ConjugateBio Partner to Develop Novel Antibody Drug Conjugate

08 يوليو 2025 07:00:00 بحسب Nasdaq GlobeNewswire

Adagene announces up to $25 million strategic investment from Sanofi

01 يوليو 2025 07:00:00 بحسب Nasdaq GlobeNewswire

Adagene to Present at Jefferies Global Healthcare Conference 2025

27 مايو 2025 07:30:00 بحسب Nasdaq GlobeNewswire

Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting

22 مايو 2025 17:05:00 بحسب Nasdaq GlobeNewswire

Adagene Appoints John Maraganore, Ph.D. as Executive Advisor

28 أبريل 2025 08:00:00 بحسب Nasdaq GlobeNewswire

Adagene Announces Upcoming Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at American Society of Clinical Oncology (ASCO) Annual Meeting

23 أبريل 2025 10:05:00 بحسب Nasdaq GlobeNewswire

Adagene to Present at Stifel’s 2025 Virtual Targeted Oncology Forum

07 أبريل 2025 08:00:01 بحسب Nasdaq GlobeNewswire

Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update

24 مارس 2025 08:00:00 بحسب Nasdaq GlobeNewswire

Adagene to Present at 11th Annual Immuno-Oncology 360⁰ Summit

13 مارس 2025 08:00:00 بحسب Nasdaq GlobeNewswire

Adagene to Present at Leerink’s Global Healthcare Conference 2025

06 مارس 2025 08:00:00 بحسب Nasdaq GlobeNewswire

Adagene Announces Investigator Initiated Phase 2 Trial for Neoadjuvant Muzastotug (ADG126) in Colorectal Cancer

27 فبراير 2025 08:00:01 بحسب Nasdaq GlobeNewswire